Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 11/20 | 0.51 |
| ▸ | AXL | P30530 | 8/20 | 0.51 |
| ▸ | MST1R | Q04912 | 4/20 | 0.51 |
| ▸ | TYRO3 | Q06418 | 4/20 | 0.51 |
| ▸ | MERTK | Q12866 | 3/20 | 0.51 |
| ▸ | PLK4 | O00444 | 1/20 | 0.51 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.51 |
| ▸ | LCK | P06239 | 1/20 | 0.51 |
| ▸ | RET | P07949 | 1/20 | 0.51 |
| ▸ | KIT | P10721 | 1/20 | 0.51 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.51 |
| ▸ | PRKACA | P17612 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | FLT3 | P36888 | 1/20 | 0.51 |
| ▸ | ABL2 | P42684 | 1/20 | 0.51 |
| ▸ | FRK | P42685 | 1/20 | 0.51 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23749324 | 0.88 | MET (0.41) | METAXLMST1RTYRO3MERTK | |
| SCHEMBL14705756 | 0.88 | MET (0.50) | METAXLMST1RTYRO3MERTK | |
| SCHEMBL721541 | 0.88 | MET (0.50) | METAXLMST1RTYRO3MERTK | |
| SCHEMBL23749393 | 0.88 | MET (0.43) | METAXLMST1RTYRO3MERTK | |
| SCHEMBL23071634 | 0.87 | MET (0.52) | METAXLMST1RTYRO3MERTK | |
| SCHEMBL3665276 | 0.86 | AXL (0.49) | METAXLMST1RTYRO3MERTK | |
| SCHEMBL23749466 | 0.85 | AXL (0.43) | METAXLMST1RTYRO3MERTK | |
| SCHEMBL30031376 | 0.85 | AXL (0.43) | METAXLMST1RTYRO3MERTK | |
| SCHEMBL23749505 | 0.85 | MET (0.48) | METAXLMST1RTYRO3MERTK | |
| SCHEMBL15946923 | 0.85 | MET (0.48) | METAXLMST1RTYRO3MERTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12202835-B2 | Substituted aromatic ring-linked dioxinoquinazolines and dioxinoquinolines as kinase inhibitors | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2025-01-21 | — | — | US | disclosed |
| US-20230172914-A1 | BIOMARKER-BASED THERAPEUTIC COMPOSITION | WELLMARKER BIO CO., LTD. (KR) | 2023-06-08 | — | — | US | disclosed |
| CN-111196814-B | Aromatic ring-linked dioxane quinazoline or quinoline compound, composition and application thereof | 北京赛特明强医药科技有限公司 | 2022-12-06 | — | — | CN | disclosed |
| US-20220002308-A1 | AROMATIC RING-LINKED DIOXINO-QUINAZOLINE OR DIOXINO-QUINOLINE COMPOUNDS, COMPOSITIONS AND USE THEREOF | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2022-01-06 | — | — | US | disclosed |
| US-20220002308-A1 | AROMATIC RING-LINKED DIOXINO-QUINAZOLINE OR DIOXINO-QUINOLINE COMPOUNDS, COMPOSITIONS AND USE THEREOF | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2022-01-06 | — | — | US | disclosed |
| EP-3865487-A1 | AROMATIC RING-LINKED DIOXANE-QUINAZOLINE OR -QUINOLINE COMPOUNDS, COMPOSITIONS AND USE THEREOF | Beijing Scitech-MQ Pharmaceuticals Limited (CN) | 2021-08-18 | — | — | EP | disclosed |
| EP-3865487-A1 | AROMATIC RING-LINKED DIOXANE-QUINAZOLINE OR -QUINOLINE COMPOUNDS, COMPOSITIONS AND USE THEREOF | Beijing Scitech-MQ Pharmaceuticals Limited (CN) | 2021-08-18 | — | — | EP | disclosed |
| EP-3819300-A1 | BIOMARKER-BASED THERAPEUTIC COMPOSITION | Wellmarker Bio Co., Ltd. (KR) | 2021-05-12 | — | — | EP | disclosed |
| CN-112771053-A | Biomarker-based therapeutic compositions | 伟迈可生物有限公司 | 2021-05-07 | — | — | CN | disclosed |
| WO-2021045279-A1 | BIOMARKER-BASED THERAPEUTIC COMPOSITION | 웰마커바이오 주식회사 | 2021-03-11 | — | — | WO | disclosed |
| US-20140343103-A1 | PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-11-20 | — | — | US | disclosed |
| EP-2782577-A2 | PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | Deciphera Pharmaceuticals, LLC. (US) | 2014-10-01 | — | — | EP | disclosed |
| WO-2014145004-A1 | PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20130317066-A1 | PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, INC. (US) | 2013-11-28 | — | — | US | disclosed |
| US-8569319-B2 | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities | Deciphera Pharmaceuticals, LLS (US) | 2013-10-29 | — | — | US | disclosed |
| WO-2013078237-A1 | N-ARYLYLMETHYLINDAZOLE MODULATORS OF PPARG | RIPKA AMY S (US) | 2013-05-30 | — | — | WO | disclosed |
| WO-2013078295-A2 | PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2013-05-30 | — | — | WO | disclosed |
| EP-2563773-A1 | PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITES | Deciphera Pharmaceuticals, LLC (US) | 2013-03-06 | — | — | EP | disclosed |
| US-20120172382-A1 | PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC. (US) | 2012-07-05 | — | — | US | disclosed |
| WO-2011139891-A1 | PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130317066-A1 | PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | MKI67, TYMP, CCNA1 | MET 2197/4885AXL 3090/4885MST1R 2902/4885 |
| US-20120172382-A1 | PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | MKI67, TYMP, CCNA1 | MET 2197/4885AXL 3090/4885MST1R 2902/4885 |
| US-20230172914-A1 | BIOMARKER-BASED THERAPEUTIC COMPOSITION | KRAS, RET, NRAS | MET 25/4885AXL 725/4885MST1R 631/4885 |
| US-20220002308-A1 | AROMATIC RING-LINKED DIOXINO-QUINAZOLINE OR DIOXINO-QUINOLINE COMPOUNDS, COMPOSITIONS AND USE THEREOF | MERTK, AXL, TYRO3 | MET 14/4885AXL 2/4885MST1R 111/4885 |
| US-12202835-B2 | Substituted aromatic ring-linked dioxinoquinazolines and dioxinoquinolines as kinase inhibitors | MERTK, AXL, TYRO3 | MET 12/4885AXL 2/4885MST1R 77/4885 |
| US-20140343103-A1 | PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | MKI67, TYMP, CCNA1 | MET 2197/4885AXL 3090/4885MST1R 2902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.